US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
This article was originally published in Scrip
Executive Summary
The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.
You may also be interested in...
FDA Finally Approves Avastin In First-Line Ovarian Cancer
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.